Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Slides:

Advertisements

Similar presentations

Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis Nataliya Y. Kashirskaya, Nikolay I. Kapranov,

Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Scott D. Sagel, Marci K. Sontag, Meg M

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis C.J. Taylor, R. Thieroff-Ekerdt, S. Shiff, L.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

David N. Sheppard Journal of Cystic Fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

A.H. Gifford Journal of Cystic Fibrosis

EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency Jamie L. Wooldridge, James.

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure I.J. Clifton, A.M. Morton, N.S. Ambrose,

Demographics of glucose metabolism in cystic fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Predicting hypoxia in cystic fibrosis patients during exposure to high altitudes Wolfgang Kamin, Birthe Fleck, Dirk-Mathias Rose, Oliver Thews, Wolfgang.

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy G. Fitch, K. Williams,

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Steven D. Strausbaugh,

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

An unusual case of abdominal pain in a patient with cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin R. Graff, David Boyd, Katrin Beckmann, Steven Caras Journal of Cystic Fibrosis Volume 8, Issue 6, Pages 370-377 (December 2009) DOI: 10.1016/j.jcf.2009.08.008 Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study design and patient disposition. AE: adverse event. Journal of Cystic Fibrosis 2009 8, 370-377DOI: (10.1016/j.jcf.2009.08.008) Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Individual subject data for (A) coefficient of fat absorption (CFA) and (B) coefficient of nitrogen absorption (CNA) during treatment with Creon or placebo. Journal of Cystic Fibrosis 2009 8, 370-377DOI: (10.1016/j.jcf.2009.08.008) Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Effect of Creon on abdominal pain (A, B), stool consistency (C, D), and flatulence (E, F), and Clinical Global Impression of Disease Severity (CGI) assessed by investigators (G) and by subjects (H). Journal of Cystic Fibrosis 2009 8, 370-377DOI: (10.1016/j.jcf.2009.08.008) Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions